OncoCyte Debt to Equity Ratio 2014-2024 | OCX
Current and historical debt to equity ratio values for OncoCyte (OCX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. OncoCyte debt/equity for the three months ending June 30, 2024 was 0.00.
| OncoCyte Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-06-30 | $0.05B | $0.02B | 2.29 |
| 2024-03-31 | $0.06B | $0.01B | 5.13 |
| 2023-12-31 | $0.05B | $0.02B | 2.66 |
| 2023-09-30 | $0.04B | $0.04B | 1.17 |
| 2023-06-30 | $0.04B | $0.04B | 1.01 |
| 2023-03-31 | $0.05B | $0.04B | 1.18 |
| 2022-12-31 | $0.07B | $0.03B | 1.92 |
| 2022-09-30 | $0.08B | $0.08B | 1.05 |
| 2022-06-30 | $0.09B | $0.08B | 1.06 |
| 2022-03-31 | $0.09B | $0.06B | 1.57 |
| 2021-12-31 | $0.09B | $0.07B | 1.45 |
| 2021-09-30 | $0.07B | $0.10B | 0.69 |
| 2021-06-30 | $0.08B | $0.10B | 0.73 |
| 2021-03-31 | $0.02B | $0.11B | 0.21 |
| 2020-12-31 | $0.02B | $0.03B | 0.66 |
| 2020-09-30 | $0.02B | $0.04B | 0.67 |
| 2020-06-30 | $0.02B | $0.04B | 0.60 |
| 2020-03-31 | $0.02B | $0.04B | 0.63 |
| 2019-12-31 | $0.01B | $0.03B | 0.29 |
| 2019-09-30 | $0.00B | $0.03B | 0.12 |
| 2019-06-30 | $0.00B | $0.03B | 0.12 |
| 2019-03-31 | $0.00B | $0.04B | 0.09 |
| 2018-12-31 | $0.01B | $0.00B | 1.78 |
| 2018-09-30 | $0.01B | $0.01B | 0.72 |
| 2018-06-30 | $0.01B | $0.01B | 0.78 |
| 2018-03-31 | $0.01B | $0.01B | 0.73 |
| 2017-12-31 | $0.01B | $0.00B | 1.32 |
| 2017-09-30 | $0.01B | $0.01B | 0.77 |
| 2017-06-30 | $0.01B | $0.01B | 1.15 |
| 2017-03-31 | $0.01B | $0.01B | 0.73 |
| 2016-12-31 | $0.01B | $0.01B | 0.47 |
| 2016-09-30 | $0.00B | $0.01B | 0.33 |
| 2016-06-30 | $0.00B | $0.00B | 0.66 |
| 2016-03-31 | $0.00B | $0.01B | 0.40 |
| 2015-12-31 | $0.00B | $0.01B | 0.22 |
| 2015-09-30 | $0.00B | $0.00B | 0.00 |
| 2015-06-30 | $0.00B | $0.00B | 0.00 |
| 2015-03-31 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.01B | $-0.00B | -5.90 |
| 2013-12-31 | $0.01B | $0.00B | 1.29 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.049B | $0.002B |
| OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $96.890B | 12.02 |
| Cencora (COR) | United States | $46.107B | 17.62 |
| DiDi Global (DIDIY) | China | $23.233B | 0.00 |
| ICON (ICLR) | Ireland | $18.679B | 16.64 |
| Revvity (RVTY) | United States | $15.535B | 26.63 |
| Avantor (AVTR) | United States | $15.498B | 23.24 |
| Natera (NTRA) | United States | $15.385B | 0.00 |
| Viatris (VTRS) | United States | $13.858B | 4.22 |
| BioMerieux (BMXMF) | France | $13.601B | 0.00 |
| Solventum (SOLV) | United States | $12.636B | 0.00 |
| CochLear (CHEOY) | Australia | $12.565B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.202B | 28.74 |
| Charles River Laboratories (CRL) | United States | $9.742B | 18.41 |
| Sonic Healthcare (SKHHY) | Australia | $8.273B | 0.00 |
| HealthEquity (HQY) | United States | $7.792B | 42.29 |
| Doximity (DOCS) | United States | $7.787B | 49.34 |
| Bausch + Lomb (BLCO) | Canada | $6.975B | 32.47 |
| Life Times (LTH) | United States | $4.762B | 31.52 |
| PACS (PACS) | United States | $4.502B | 0.00 |
| Sotera Health (SHC) | United States | $4.367B | 23.36 |
| Organon (OGN) | United States | $4.239B | 4.28 |
| Surgery Partners (SGRY) | United States | $3.778B | 41.86 |
| BrightSpring Health Services (BTSG) | United States | $3.070B | 65.30 |
| Ardent Health Partners (ARDT) | United States | $2.577B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.546B | 0.00 |
| Concentras Parent (CON) | United States | $2.480B | 0.00 |
| Premier (PINC) | United States | $2.271B | 11.34 |
| GoodRx Holdings (GDRX) | United States | $2.254B | 84.86 |
| GeneDx Holdings (WGS) | United States | $2.057B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.575B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.507B | 7.57 |
| Progyny (PGNY) | United States | $1.425B | 25.06 |
| Establishment Labs Holdings (ESTA) | $1.338B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.319B | 12.91 |
| CareDx (CDNA) | United States | $1.228B | 0.00 |
| Agilon Health (AGL) | United States | $1.123B | 0.00 |
| Embecta (EMBC) | United States | $0.864B | 5.76 |
| InnovAge Holding (INNV) | United States | $0.822B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| SBC Medicals (SBC) | United States | $0.722B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.488B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.483B | 0.00 |
| Enhabit (EHAB) | United States | $0.382B | 33.04 |
| DocGo (DCGO) | United States | $0.355B | 13.35 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.309B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.255B | 0.00 |
| ModivCare (MODV) | United States | $0.232B | 7.37 |
| Beauty Health (SKIN) | United States | $0.211B | 0.00 |
| Biodesix (BDSX) | United States | $0.195B | 0.00 |
| LifeMD (LFMD) | United States | $0.192B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.178B | 0.00 |
| MultiPlan (MPLN) | United States | $0.136B | 0.00 |
| Nutex Health (NUTX) | United States | $0.127B | 0.00 |
| So-Young (SY) | China | $0.092B | 22.35 |
| Harvard Apparatus Regenerative Technology (HRGN) | United States | $0.059B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.057B | 0.00 |
| NeueHealth (NEUE) | United States | $0.041B | 1.63 |
| Co-Diagnostics (CODX) | United States | $0.039B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.036B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.027B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| Oncology Institute (TOI) | United States | $0.021B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| KindlyMD (KDLY) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |